Culhane Rose, Zaborowski Alexandra M, Hill Arnold D K
Department of Breast Surgery, Beaumont Hospital, P.O. Box 1297 Dublin 9, Ireland.
Cancers (Basel). 2024 Sep 26;16(19):3267. doi: 10.3390/cancers16193267.
Menopausal symptoms negatively impact quality of life in breast cancer survivors. The paucity of data on the impact of Menopausal Hormone Therapy (MHT) on oncological outcomes in these patients limits informed clinical discussion. Defining the risk of cancer recurrence with MHT is central to the appraisal of risk/benefit, particularly with low-risk disease (based on genomic profile). The aim of this review is to summarize the current data evaluating MHT in breast cancer patients. A systematic review of the literature was performed to evaluate the impact of MHT on oncological outcomes in breast cancer survivors. Three major databases (PubMed, EMBASE and Medline) were searched. The review included all prospective studies published in English. Four randomized control trials and four non-randomized prospective studies were identified. An increase in breast cancer recurrence with MHT was observed in the early randomized trials whilst no increased risk of recurrence was reported in the observational studies. There remains a need to quantify MHT-related recurrence risk in patients with molecularly favorable disease.
更年期症状会对乳腺癌幸存者的生活质量产生负面影响。关于更年期激素疗法（MHT）对这些患者肿瘤学结局影响的数据匮乏，这限制了明智的临床讨论。确定MHT导致癌症复发的风险对于评估风险/益处至关重要，尤其是对于低风险疾病（基于基因组特征）。本综述的目的是总结目前评估乳腺癌患者MHT的相关数据。我们对文献进行了系统综述，以评估MHT对乳腺癌幸存者肿瘤学结局的影响。检索了三个主要数据库（PubMed、EMBASE和Medline）。该综述纳入了所有以英文发表的前瞻性研究。共识别出四项随机对照试验和四项非随机前瞻性研究。早期随机试验中观察到MHT会增加乳腺癌复发率，而观察性研究中未报告复发风险增加。对于分子特征良好的疾病患者，仍需要量化与MHT相关的复发风险。
